Novel cleaved iridoid compound and preparation method, pharmaceutical composition and application thereof

By extracting and isolating the novel cyclic cyclic ether terpene compound (±)-Cornuscone from dogwood, the problem of insufficient anti-inflammatory activity in the prior art was solved, and a significant anti-inflammatory effect was achieved, which was better than the first-line anti-inflammatory drug indomethacin.

CN118666793BActive Publication Date: 2025-04-18CHINA JAPAN FRIENDSHIP HOSPITAL
0 Cites 0 Cited by

Patent Information

Application Number
CN202410647905.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-23
Publication Date
2025-04-18
Estimated Expiration
2044-05-23

AI Technical Summary

Technical Problem

The prior art has the problem of insufficient anti-inflammatory activity in the treatment of inflammation-related diseases, especially with poor effect compared with the first-line anti-inflammatory drug indomethacin.

Method used

A novel cyclic cyclic ether terpene compound (±)-Cornuscone was extracted and isolated from Cornus cone, and the compound was prepared by a multi-step extraction and purification process. The structure of this compound is shown in formula (1) and has significant anti-inflammatory activity.

Benefits of technology

Compound (±)-Cornuscone significantly inhibits the release of NO in lipopolysaccharide-induced NO in RAW 264.7 cells, exhibits better anti-inflammatory activity than indomethacin, and has the potential to develop drugs for the treatment of various inflammation-related diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention belongs to the field of medical technology, and specifically discloses a novel scissoric terpenoid compound and a preparation method, a pharmaceutical composition and an application thereof. The scissoric terpenoid compound (±)-Cornuscone provided by the present invention has not been reported yet. Experimental results show that the scissoric terpenoid compound provided by the present invention has significant anti-inflammatory activity on lipopolysaccharide-induced RAW 264.7 cells, which is significantly better than the positive drug indomethacin, and can be used to develop drugs for the treatment of various inflammation-related diseases, including but not limited to arthritis, conjunctivitis, pneumonia, hepatitis, nephritis, gastroenteritis, metabolic syndrome, diabetes, cancer, etc.
Need to check novelty before this filing date? Find Prior Art